Hidroxicarbamida Hikma (Hydroxycarbamide)

Hydroxycarbamide (Hidroxicarbamida Hikma) is employed in several hematologic and oncologic indications where suppression of abnormal cell proliferation is required.

• Sickle cell disease – to reduce the frequency of painful vaso‑occlusive crises.
• Chronic myelogenous leukemia – as part of disease‑modifying therapy.
• Polycythemia vera – to control elevated red blood cell mass.
• Essential thrombocythemia – to lower platelet counts and reduce thrombotic risk.
• Melanoma – in selected cases as an adjunctive antineoplastic agent.

• Hydroxycarbamide exerts its antineoplastic effect by binding to the M2 subunit of ribonucleotide reductase, the enzyme responsible for converting ribonucleotides to deoxyribonucleotides. This inhibition lowers intracellular deoxyribonucleotide pools, thereby limiting DNA synthesis and repair in rapidly dividing cells. The resulting DNA replication stress leads to cell cycle arrest, particularly in the S phase, and promotes apoptosis of malignant or abnormal hematopoietic cells.

Hydroxycarbamide may cause a range of adverse reactions, varying from mild to severe. The frequency and severity of these effects depend on dose, duration of therapy, and individual patient factors.

Common

• Nausea or vomiting, often mild and transient.
• Decreased appetite leading to weight loss.
• Mild fatigue or generalized weakness.
• Transient skin discoloration (hyperpigmentation), especially on the face.
• Low white‑blood‑cell counts (leukopenia) or neutropenia, usually reversible.
• Elevated liver enzymes indicating mild hepatic stress.

Serious

• Severe bone‑marrow suppression causing anemia, thrombocytopenia, or pancytopenia.
• Acute kidney injury with rising creatinine levels.
• Life‑threatening infections due to profound neutropenia.
• Severe dermatologic reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary toxicity, including interstitial pneumonitis or fibrosis.
• Rare occurrence of secondary malignancies, such as acute leukemia.

Before initiating Hidroxicarbamida Hikma, clinicians should evaluate several safety considerations to minimize risk and ensure appropriate monitoring.

• Baseline complete blood count and periodic monitoring during therapy.
• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Avoid use in pregnant or breastfeeding women unless benefits outweigh risks, as fetal safety is not established.
• Caution in patients with a history of severe infections or immunosuppression.
• Monitor for signs of skin discoloration or dermatologic reactions.
• Evaluate for potential drug‑induced secondary malignancies with long‑term use.
• Ensure patient education on infection precautions and prompt reporting of adverse symptoms.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or increasing toxicity. Relevant interactions are grouped below.

Avoid

• Concurrent use with other myelosuppressive agents (e.g., chemotherapy, azathioprine) that may exacerbate bone‑marrow depression.
• Strong CYP2C9 inhibitors (e.g., fluconazole) that could raise hydroxycarbamide plasma levels.

Use with caution

• Allopurinol, which may increase risk of hematologic toxicity; monitor blood counts closely.
• NSAIDs, which can worsen renal function when combined with hydroxycarbamide.
• Live vaccines, due to impaired immune response.
• Antihypertensive agents that affect renal perfusion, requiring renal function monitoring.